Autopsy report · NCT03452137
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Cause of deathOther
“Decision to terminate the study as its primary endpoint of investigator-assessed event free survival (INV-EFS) was not met at its final EFS analysis. No new safety signals were identified.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 5 years 11 months before it stopped.
- 406 participants enrolled.
- Results were posted on the registry 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Conditions
- Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- Atezolizumab; Placebo
- Participants
- 406
- Sites
- 135
- Countries
- Australia, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Poland and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.